• Ironwood Pharmaceuticals filed an amended Form 8-K to add compensation details tied to Ronald Silver’s appointment as interim chief financial officer, effective May 15, 2026.
• The amendment discloses a monthly interim assignment fee of USD 12,250, payable until a permanent CFO is appointed or the interim assignment ends.
• It also reports a May 19, 2026 grant of 25,000 restricted stock units, vesting over two years with 50% vesting on each anniversary of the grant date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-065140), on May 21, 2026, and is solely responsible for the information contained therein.